Replimune FY26 net loss widens to $313.94 million; R&D expenses rise to $221.18 million

Replimune

Replimune

REPL

0.00
  • Replimune fiscal year ended March 31, 2026 net loss widened to USD 313.94 million; loss per share widened to USD 3.38.
  • R&D expense rose to USD 221.18 million; SG&A expense climbed to USD 98.74 million.
  • Cash, cash equivalents and short-term investments fell to USD 268.89 million; working capital dropped to USD 220.89 million.
  • FDA accepted the resubmitted BLA for RP1 with nivolumab in advanced melanoma; goal date Aug. 2, 2026, advisory committee expected late July.
  • Replimune expects existing cash to fund operations into the first quarter of calendar 2027, including RP1 commercialization scale-up in skin cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290800PRIMZONEFULLFEED9753983) on June 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.